Newsgather

CRISPR

Estable5 noticias4 fuentesÚltima actualización: 1/7/2026

Últimas noticias

Intellia's CRISPR Treatment Shows 87% Reduction in Hereditary Angioedema Attacks
En desarrollo
Ciencia·27/4/2026Resumen IA

Intellia's CRISPR Treatment Shows 87% Reduction in Hereditary Angioedema Attacks

Intellia Therapeutics' CRISPR-based treatment for hereditary angioedema met its goals in a Phase 3 trial, reducing attacks by 87% compared with placebo. The one-time infusion therapy edits genes directly in the liver and achieved 62% of patients being attack-free six months after treatment. The company has started a rolling FDA application and plans to launch in the first half of next year if approved.

C
CNBC
2 min de lectura